HK1144306A1 - 激酶抑制劑及其用途 - Google Patents

激酶抑制劑及其用途

Info

Publication number
HK1144306A1
HK1144306A1 HK10110773.0A HK10110773A HK1144306A1 HK 1144306 A1 HK1144306 A1 HK 1144306A1 HK 10110773 A HK10110773 A HK 10110773A HK 1144306 A1 HK1144306 A1 HK 1144306A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
HK10110773.0A
Other languages
English (en)
Inventor
Alyssa Panitch
Brandon Seal
Brian Ward
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of HK1144306A1 publication Critical patent/HK1144306A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK10110773.0A 2007-08-07 2010-11-18 激酶抑制劑及其用途 HK1144306A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96394107P 2007-08-07 2007-08-07
US99497007P 2007-09-24 2007-09-24
PCT/US2008/072525 WO2009021137A2 (en) 2007-08-07 2008-08-07 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
HK1144306A1 true HK1144306A1 (zh) 2011-02-11

Family

ID=40342047

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10110773.0A HK1144306A1 (zh) 2007-08-07 2010-11-18 激酶抑制劑及其用途

Country Status (7)

Country Link
US (2) US8741849B2 (zh)
EP (1) EP2185698B1 (zh)
JP (1) JP5703466B2 (zh)
DK (1) DK2185698T3 (zh)
ES (1) ES2547229T3 (zh)
HK (1) HK1144306A1 (zh)
WO (1) WO2009021137A2 (zh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
EP2155228B1 (en) 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
EP2185698B1 (en) 2007-08-07 2015-04-22 Purdue Research Foundation Kinase inhibitors and uses thereof
AU2009322865B2 (en) * 2008-10-20 2013-07-18 Moerae Matrix, Inc. Polypeptide for treating or preventing adhesions
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
ES2685505T3 (es) * 2008-12-10 2018-10-09 Purdue Research Foundation Inhibidor de cinasas basado en péptidos de permeación celular
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
WO2011149964A2 (en) * 2010-05-24 2011-12-01 Moerae Matrix, Inc., Methods for treating or preventing vascular graft failure
CA3154024C (en) 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
BR112013026313A8 (pt) 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CN102949722A (zh) * 2011-08-26 2013-03-06 中国医学科学院放射医学研究所 基于p38抑制剂和细胞生长因子的新颖药物组合物
CA2853722A1 (en) 2011-10-27 2013-05-02 Mayo Foundation For Medical Education And Research Inhibiting g protein coupled receptor 6 kinase polypeptides
WO2013067050A1 (en) * 2011-10-31 2013-05-10 University Of Utah Research Foundation Genetic alterations in glioblastoma
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
EP2827869A4 (en) 2012-03-23 2015-09-23 Dennis Brown COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
WO2014160364A1 (en) * 2013-03-13 2014-10-02 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
WO2014169256A2 (en) * 2013-04-11 2014-10-16 Vanderbilt University Polyplexes
GB201314610D0 (en) 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
WO2015057461A2 (en) 2013-10-18 2015-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use
CN103739678B (zh) * 2013-12-31 2015-09-02 刘培臣 抑制粘附斑激酶多肽及其应用
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US9902739B2 (en) 2014-04-21 2018-02-27 Mayo Foundation For Medical Education And Research Small molecule inhibitors of G protein coupled receptor 6 kinases polypeptides
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
AU2015300966A1 (en) * 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
US10512651B2 (en) * 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
WO2016081475A1 (en) 2014-11-17 2016-05-26 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
KR20170102900A (ko) 2015-01-08 2017-09-12 모레 매트릭스 인코포레이티드 Mk2 저해제 펩타이드의 제형
AU2016229017A1 (en) * 2015-03-12 2017-09-28 Moerae Matrix, Inc. Use of MK2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
AU2016291676B2 (en) 2015-07-16 2020-04-30 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
WO2017147526A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
US20210380639A1 (en) * 2018-05-15 2021-12-09 Interk Peptide Therapeutics Limited Activating Agents
CN112399970A (zh) 2018-05-15 2021-02-23 英特肽治疗有限公司 肽活化剂
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
US20220089599A1 (en) * 2018-09-12 2022-03-24 Purdue Research Foundation Alkynyl nicotinamide compounds as kinase inhibitors
EP3908577A4 (en) * 2019-01-11 2022-06-29 The Board of Trustees of the Leland Stanford Junior University Pi4-kinase inhibitors with anti-cancer activity
WO2021097407A2 (en) * 2019-11-15 2021-05-20 Regents Of The University Of Colorado, A Body Corporate Novel peptide compositions and methods of treating neurological injury
CN114605497B (zh) * 2021-02-10 2023-04-28 北京欣安诚科技有限公司 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途
CN115976033B (zh) * 2022-12-14 2024-05-17 西南大学 瓜实蝇tssk1和tssk3基因及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) * 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) * 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) * 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU570013B2 (en) * 1982-10-08 1988-03-03 Glaxo Group Limited Medicament inhaler
CA1272917A (en) * 1985-07-30 1990-08-21 Paul Kenneth Rand Devices for administering medicaments to patients
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
AU654483B2 (en) * 1990-04-18 1994-11-10 University Of Utah Research Foundation Crosslinked hydrogels containing azobonds
CA2118513A1 (en) 1992-04-24 1993-11-11 David A. Zarling In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE196311T1 (de) * 1993-12-09 2000-09-15 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
AU1818299A (en) 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
US7041814B1 (en) * 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
JP2002510336A (ja) * 1998-04-11 2002-04-02 エレカッパ・ユウロテラピッチ・ソシエタ・ペル・アチオニ 水溶性ケトプロフェン塩を含有する薬学的調製物及びその使用方法
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7615373B2 (en) * 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
ATE323517T1 (de) * 2000-08-15 2006-05-15 Surmodics Inc Matrix zur aufnahme von arzneimitteln
EP1351702B1 (en) * 2000-12-08 2015-03-04 Bioprovar Corporation Trem-1 splice variant for use in modifying immune responses
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
DE10118774A1 (de) 2001-04-17 2002-10-31 Jerini Ag Verfahren zur Bestimmung der Substratspezifität einer enzymatischen Aktivität und Vorrichtung hierzu
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DK1523323T3 (da) * 2001-08-23 2013-10-28 Univ Arizona Reagenser og fremgangsmåder til behandlinger i den glatte muskulatur
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
IL163575A0 (en) * 2002-02-21 2005-12-18 Univ Rockefeller Compositions and method for regulation of calcium-dependent signalling in brain
US20040005686A1 (en) 2002-03-07 2004-01-08 Pharmacia Corporation Crystalline structure of human MAPKAP kinase-2
WO2003084481A2 (en) * 2002-04-01 2003-10-16 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
CN1735687A (zh) 2002-08-02 2006-02-15 惠氏公司 Mk2相互作用蛋白
AU2003297431A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
ES2268631T3 (es) 2003-02-21 2007-03-16 Arizona Board Of Regents Utilizacion de hsp20 para estimular la cicatrizacion de heridas y/o para reducir la formacion de cicatrices.
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
CA2542639A1 (en) 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor
EP1766412B1 (en) 2004-05-21 2009-04-01 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
US20060024264A1 (en) * 2004-07-23 2006-02-02 Kenichi Kuroda Antimicrobial copolymers and uses thereof
JP2008519861A (ja) * 2004-11-12 2008-06-12 マサチューセッツ・インスティテュート・オブ・テクノロジー 細胞増殖性疾患を治療するための方法および組成物
WO2006071456A2 (en) 2004-12-02 2006-07-06 The University Of North Carolina At Chapel Hill Inhibition of hsp27 phosphorylation for treatment of blistering disorders
CA2603116A1 (en) * 2005-03-29 2006-10-05 The Regents Of The University Of California Controlling stem cell destiny with tunable network
EP1868629B1 (en) * 2005-04-15 2014-10-22 Arizona Biomedical Research Commission Therapeutic fusion peptides for the treatment of metastatic cancer
ES2628031T3 (es) * 2005-10-26 2017-08-01 Genesis Technologies Limited Matrices de regeneración tisular acelulares bioabsorbibles producidas mediante incubación de productos sanguíneos acelulares
CA2626868A1 (en) * 2005-11-01 2007-05-10 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizo Na State University Novel protein transduction domains and uses therefor
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
BRPI0714383A2 (pt) 2006-07-12 2013-04-30 Univ Arizona mÉtodos para tratar e limitar desordens fibràticas e queloides
EP2155228B1 (en) * 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
EP2185698B1 (en) 2007-08-07 2015-04-22 Purdue Research Foundation Kinase inhibitors and uses thereof
WO2009123759A2 (en) 2008-04-02 2009-10-08 Moerae Matrix, Inc. Therapeutic uses of biocompatible biogel compositions
AU2009322865B2 (en) * 2008-10-20 2013-07-18 Moerae Matrix, Inc. Polypeptide for treating or preventing adhesions
ES2685505T3 (es) 2008-12-10 2018-10-09 Purdue Research Foundation Inhibidor de cinasas basado en péptidos de permeación celular
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2011149964A2 (en) * 2010-05-24 2011-12-01 Moerae Matrix, Inc., Methods for treating or preventing vascular graft failure
BR112013026313A8 (pt) 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular

Also Published As

Publication number Publication date
JP5703466B2 (ja) 2015-04-22
US20140342993A1 (en) 2014-11-20
JP2010535508A (ja) 2010-11-25
US20090149389A1 (en) 2009-06-11
WO2009021137A3 (en) 2009-07-09
EP2185698A2 (en) 2010-05-19
ES2547229T3 (es) 2015-10-02
US9447158B2 (en) 2016-09-20
US8741849B2 (en) 2014-06-03
WO2009021137A2 (en) 2009-02-12
DK2185698T3 (en) 2015-07-27
EP2185698A4 (en) 2012-03-28
US20130184221A9 (en) 2013-07-18
EP2185698B1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
HUS2200052I1 (hu) Imidazotriazinok és imidazopirimidinek mint kinázgátlók
HK1144306A1 (zh) 激酶抑制劑及其用途
ZA201004055B (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
HK1140767A1 (zh) 激酶抑制劑
IL197381A0 (en) Kinase inhibitor
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
ZA201003420B (en) Protein kinase inhibitors and use thereof
IL207415A0 (en) Protein kinase inhibitors and use thereof
HK1137756A1 (zh) 取代二氫吡唑啉酮和它們作爲 -脯氨酰- -羥化酶抑制劑的用途
EP2379076A4 (en) PHOSPHODIESTERASE HEMMER AND ITS USES
ZA200908943B (en) Pyrazolopyrimidinone kinase inhibitor
IL197981A0 (en) Kinase inhibitors
GB0715470D0 (en) IKK- serine-threonine protein kinase inhibitors

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: ADDITION OF INVENTOR: WARD, BRIAN

Effective date: 20160225

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210807